Research
Research at IPS
Faculty and students at IPS engage in innovative, multidisciplinary research across pharmaceutical and health sciences, addressing emerging healthcare challenges and contributing to advances in education, research, and patient care.
Research Areas
Pharmacogenomics & Precision Medicine
Genetic and molecular factors influencing drug response, treatment outcomes, and personalized therapy.
Endocrinology, Metabolic Pharmacology & Toxicology
Hormonal disorders, metabolic diseases, diabetes, and therapeutic interventions.
Neuropharmacology & Neuroscience
Investigation of the nervous system, neurological disorders, and novel pharmacological approaches for neurotherapeutics.
Pharmacological Screening Natural products Research
Discovery, development, and formulation of novel therapeutic agents. Investigation of medicinal plants and natural compounds for therapeutic potential.
Drug Delivery & Pharmaceutical Biomaterials Tissue Engineering & Regenerative Medicine
Development of innovative drug delivery systems and biocompatible pharmaceutical materials.
Nanomedicine & Nanotechnology Advanced Drug Delivery Systems Pharmaceutical Formulation Development
Application of nanotechnology in drug development, diagnosis, and targeted therapy.
Pharmacoepidemiology, Pharmacovigilance and Drug Safety.
Research on drug use, adverse drug reactions, safety monitoring, and risk assessment.
Publications
Pulled automatically from each faculty member's profile.
- Investigating the Role of Vitamin D in Enhancing Duloxetine and Fluoxetine Efficacy: Mechanistic Insights Into NRF2 Activation, Oxidative Stress, and Neurochemical Modulation — Dr. Muhammad Waseem Khan, Pharmaceutics · 2025
- Serum lipid profile alterations in type 2 diabetes mellitus patients · 2024
- Endothelial dysfunction in early-stage hypertension: a cohort study · 2024
- Prevalence of non-communicable disease risk factors in urban Peshawar · 2024
- Histopathological spectrum of breast lesions in a tertiary care setting · 2024
- Association of Human Leukocyte Antigen (HLA) Class II Alleles of DQB1 (DQB1*03:02) (DQB1*06:02) and DRB1 (DRB1*04:01) with Type-1 Diabetes Patients of Khyber Pakhtunkhwa, Pakistan — Ms. Hira Siyar, Pharmacology · 2024
- Adverse drug reaction reporting trends in tertiary care hospitals · 2024
- Association of Human Leukocyte Antigen (HLA) Class II Alleles of DQB1 (DQB1*03:02) (DQB1*06:02) and DRB1 (DRB1*04:01) with Type-1 Diabetes Patients of Khyber Pakhtunkhwa, Pakistan — Ms. Kiran Ijaz, Pharmaceutical Chemistry · 2024
Research Projects
Pharmacokinetic profile of Carbamazepine and valproic acid therapy in management of epilepsies with reference to SNPs in EPHX1, SCN1A and SCN2A genes in the population of Khyber Pakhtunkhwa
Principal Investigator: Prof. Dr. Niaz Ali Funding Agency: Higher Education Commission (HEC), Pakistan Grant Amount: Rs. 16,976,250 Award No.: 20-4092/NRPU/R&D/HEC 2015/230 Award Date: 08 September 2015
Synergistic effect of current statins and calcium channel blockers: An EC50 based in vitro drug interaction study
Funding Agency: Ministry of Education, Government of Saudi Arabia Grant No.: SU-ANN-202201 Project Status: Executed Project Duration: 2022–2023 Principal Investigator: Prof. Dr. Niaz Ali
Collaborations
IPS collaborates with academic and healthcare institutions on joint research and training initiatives.
Khyber Medical University
Parent institution and primary academic partner.
Khyber Teaching Hospital (KTH) Peshawar
Rehman Medical Institute (RMI) Peshawar
Peshawar Institute of Cardiology (PIC) Peshawar
Hayatabad Medical Complex (HMC) Peshawar
North West General Hospital and Research Centre, Peshawar
Lady Reading Hospital (LRH) Peshawar
Conferences & Workshops
Seminars, workshops and conferences are listed on the News & Events page.
View News & Events